Insider Selling: Ralliant (NYSE:RAL) CEO Sells $928,675.44 in Stock

Posted by Stanley Muller on Aug 18th, 2026

Ralliant Corporation (NYSE:RAL – Get Free Report) CEO Tamara Newcombe sold 12,936 shares of Ralliant stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $71.79, for a total value of $928,675.44. Following the completion of the sale, the chief executive officer directly owned 251,967 shares in the company, valued at approximately $18,088,710.93. This represents a 4.88% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ralliant Stock Down 3.5%

NYSE:RAL traded down $2.54 during trading hours on Tuesday, reaching $69.42. 1,336,205 shares of the stock were exchanged, compared to its average volume of 1,694,804. The stock has a market cap of $7.68 billion, a PE ratio of -6.40, a PEG ratio of 2.69 and a beta of 1.61. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $75.41. The firm has a 50 day moving average of $68.82 and a 200 day moving average of $55.58. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.00.

Ralliant (NYSE:RAL – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. The company had revenue of $567.80 million for the quarter. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, equities analysts expect that Ralliant Corporation will post 2.87 earnings per share for the current year.

Ralliant Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Shareholders of record on Tuesday, September 8th will be paid a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 8th. Ralliant’s payout ratio is presently -1.84%.

Hedge Funds Weigh In On Ralliant

Institutional investors have recently bought and sold shares of the business. Danske Bank A S bought a new position in shares of Ralliant during the 4th quarter worth approximately $25,000. Dunhill Financial LLC bought a new stake in Ralliant in the 2nd quarter valued at $25,000. Allworth Financial LP lifted its holdings in Ralliant by 134.4% during the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after purchasing an additional 293 shares during the last quarter. Palisade Asset Management LLC acquired a new stake in Ralliant during the 3rd quarter valued at $26,000. Finally, BOKF NA bought a new position in Ralliant during the third quarter worth $29,000.

Analyst Ratings Changes

RAL has been the topic of several analyst reports. Royal Bank Of Canada upped their target price on Ralliant from $71.00 to $73.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ralliant in a research report on Friday, July 31st. TD Cowen upped their price objective on Ralliant from $70.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Wall Street Zen downgraded Ralliant from a “strong-buy” rating to a “buy” rating in a report on Tuesday, August 11th. Finally, Truist Financial reissued a “buy” rating and issued a $82.00 target price (up from $68.00) on shares of Ralliant in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $75.70.

Check Out Our Latest Research Report on Ralliant

About Ralliant

(Get Free Report)

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.